1. Home
  2. FTNT vs VRTX Comparison

FTNT vs VRTX Comparison

Compare FTNT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortinet Inc.

FTNT

Fortinet Inc.

HOLD

Current Price

$170.88

Market Cap

125.4B

Sector

Technology

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$501.64

Market Cap

128.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTNT
VRTX
Founded
2000
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
125.4B
128.8B
IPO Year
2009
2006

Fundamental Metrics

Financial Performance
Metric
FTNT
VRTX
Price
$170.88
$501.64
Analyst Decision
Hold
Buy
Analyst Count
44
32
Target Price
$167.91
★ $571.46
AVG Volume (30 Days)
★ 3.0M
1.0M
Earning Date
10-28-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
7.08
★ 836.54
EPS
1.54
★ 8.33
Revenue
★ $6,799,600,000.00
$2,488,652,000.00
Revenue This Year
$19.42
$10.54
Revenue Next Year
$11.23
$9.74
P/E Ratio
$109.68
★ $59.93
Revenue Growth
14.17
★ 46.20
52 Week Low
$73.55
$403.16
52 Week High
$197.13
$560.25

Technical Indicators

Market Signals
Indicator
FTNT
VRTX
Relative Strength Index (RSI) 43.02 44.56
Support Level $146.01 $498.58
Resistance Level $172.11 $506.93
Average True Range (ATR) 5.60 11.23
MACD -2.41 -0.60
Stochastic Oscillator 14.52 36.97

Price Performance

Historical Comparison
FTNT
VRTX

About FTNT Fortinet Inc.

Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: